Enhanced Growth-Suppressive Activity of New Curcumin Analogues in Prostate Cancer Cells

Strategic Insights -

Researchers from Ohio State University have discovered new curcumin analogues, FLLL11 and FLLL12, which exhibit enhanced growth-suppressive activity and inhibit key cancer-promoting pathways in breast and prostate cancer cells. The study reveals that these analogues are more potent than curcumin in inhibiting cell viability, cell migration, and colony formation in soft agar, and inducing apoptosis in cancer cells. The findings suggest that FLLL11 and FLLL12 may have translational potential as chemopreventive or therapeutic agents for breast and prostate cancers.

Key Takeaways:

  • FLLL11 and FLLL12, two new curcumin analogues, were found to be more potent than curcumin in inhibiting cell viability in eight different breast and prostate cancer cell lines.
  • FLLL11 and FLLL12 exhibited IC(50) values of 0.3-5.7 and 0.3-3.8 micromol/L, respectively, while curcumin showed IC(50) values between 14.4-50 micromol/L.
  • The analogues inhibited AKT phosphorylation, downregulated the expression of HER2/neu, and inhibited phosphorylation of signal transducer and activator of transcription (STAT) 3, an oncogene frequently found to be persistently active in many cancer types.
  • FLLL11 and FLLL12 were also found to inhibit cell migration and colony formation in soft agar, and induce apoptosis in cancer cells.
  • The study's findings indicate that FLLL11 and FLLL12 may have translational potential as chemopreventive or therapeutic agents for breast and prostate cancers.

Statistics:

  • IC(50) values for FLLL11 and FLLL12 ranged from 0.3-5.7 and 0.3-3.8 micromol/L, respectively, while curcumin showed IC(50) values between 14.4-50 micromol/L.
  • FLLL11 and FLLL12 inhibited cell viability by 50% at concentrations of 0.3-5.7 and 0.3-3.8 micromol/L, respectively.
  • The analogues inhibited AKT phosphorylation by 50% at concentrations of 1-2 micromol/L.
  • FLLL11 and FLLL12 inhibited cell migration by 50% at concentrations of 1-5 micromol/L.

Sources:

  • Lin, L., et al. (2009). New curcumin analogues exhibit enhanced growth-suppressive activity and inhibit AKT and signal transducer and activator of transcription 3 phosphorylation in breast and prostate cancer cells. Cancer Science, 100(9), 1719-1727.
  • Cancer Weekly editors (2009). Enhanced Growth-Suppressive Activity of New Curcumin Analogues in Prostate Cancer Cells. Cancer Weekly via NewsRx.com.